{"id":70084,"date":"2026-07-16T16:13:25","date_gmt":"2026-07-16T08:13:25","guid":{"rendered":"https:\/\/flcube.com\/?p=70084"},"modified":"2026-07-16T16:13:26","modified_gmt":"2026-07-16T08:13:26","slug":"novo-nordisk-secures-eu-approval-for-wegovy-pill-first-oral-semaglutide-25mg-for-obesity-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70084","title":{"rendered":"Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Novo Nordisk<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) announced today that the <strong>European Commission (EC)<\/strong> has granted <strong>marketing authorization<\/strong> for <strong>Wegovy pill<\/strong> (once-daily oral semaglutide 25 mg) for treating adults with <strong>obesity (BMI \u226530 kg\/m\u00b2)<\/strong> or <strong>overweight (BMI \u226527 kg\/m\u00b2)<\/strong> with at least one weight-related comorbidity. The approval follows a <strong>positive opinion<\/strong> from the <strong>European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP)<\/strong> issued in May 2026.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-key-details\" class=\"wp-block-heading\">Regulatory Milestone | Key Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Novo Nordisk (NYSE: NVO)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Wegovy pill (oral semaglutide 25 mg)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>July 15, 2026<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Obesity (BMI \u226530) or overweight (BMI \u226527) with comorbidity<\/td><\/tr><tr><td><strong>Dosing<\/strong><\/td><td>Once-daily oral administration<\/td><\/tr><tr><td><strong>Adjunct Therapy<\/strong><\/td><td>Reduced-calorie diet and increased physical activity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-evidence-oasis-trial-program\" class=\"wp-block-heading\">Clinical Evidence | OASIS Trial Program<\/h2>\n\n\n\n<h3 id=\"h-primary-efficacy-results\" class=\"wp-block-heading\">Primary Efficacy Results<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Weight Loss:<\/strong> Approximately <strong>17%<\/strong> with oral semaglutide 25 mg vs. <strong>3%<\/strong> with placebo<\/li>\n\n\n\n<li><strong>High Responders:<\/strong> Around <strong>one in three individuals<\/strong> achieved <strong>\u226520% weight loss<\/strong><\/li>\n\n\n\n<li><strong>Trial Population:<\/strong> Adults with obesity or overweight with at least one weight-related comorbidity<\/li>\n\n\n\n<li><strong>Study Design:<\/strong> OASIS 4 trial within extensive OASIS clinical program<\/li>\n\n\n\n<li><strong>Intervention:<\/strong> Oral semaglutide combined with lifestyle intervention<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-safety-profile\" class=\"wp-block-heading\">Safety Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Consistency:<\/strong> Safety and tolerability profile consistent with established <strong>injectable semaglutide<\/strong><\/li>\n\n\n\n<li><strong>Established Track Record:<\/strong> Leverages known safety data from injectable GLP-1 receptor agonist class<\/li>\n\n\n\n<li><strong>Gastrointestinal Events:<\/strong> Expected side effect profile similar to other GLP-1 therapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-commercial-implications\" class=\"wp-block-heading\">Market Impact &amp; Commercial Implications<\/h2>\n\n\n\n<h3 id=\"h-competitive-positioning\" class=\"wp-block-heading\">Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First oral GLP-1<\/strong> approved in Europe specifically for obesity treatment at 25 mg dose<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Offers needle-free alternative to injectable Wegovy while maintaining high efficacy<\/li>\n\n\n\n<li><strong>Patient Preference:<\/strong> Addresses significant market demand for oral administration options<\/li>\n\n\n\n<li><strong>Adherence Potential:<\/strong> May improve long-term treatment adherence compared to injectable formulations<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-european-market-opportunity\" class=\"wp-block-heading\">European Market Opportunity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity Prevalence:<\/strong> Affects over <strong>59% of adults<\/strong> across EU member states<\/li>\n\n\n\n<li><strong>Addressable Population:<\/strong> Estimated <strong>100+ million Europeans<\/strong> eligible for treatment<\/li>\n\n\n\n<li><strong>Reimbursement Landscape:<\/strong> Varies by country, with growing recognition of obesity as chronic disease requiring pharmacological intervention<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Expected premium pricing reflecting clinical efficacy and convenience benefits<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-strategic-significance-for-novo-nordisk\" class=\"wp-block-heading\">Strategic Significance for Novo Nordisk<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">This approval represents a <strong>major expansion<\/strong> of Novo Nordisk&#8217;s obesity franchise in Europe:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Enhancement:<\/strong> Complements existing injectable Wegovy offering<\/li>\n\n\n\n<li><strong>Market Leadership:<\/strong> Strengthens position against emerging competitors in GLP-1 space<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Creates additional revenue stream from same patient population preferring oral administration<\/li>\n\n\n\n<li><strong>Global Rollout:<\/strong> European approval supports regulatory submissions in other major markets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The oral formulation leverages Novo Nordisk&#8217;s proprietary <strong>absorption-enhancing technology<\/strong>, which enables effective delivery of peptide therapeutics through oral administration\u2014a significant scientific achievement that differentiates the company from competitors still reliant on injectable delivery systems.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial performance. Actual results may differ due to risks including reimbursement decisions, competitive pressures, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NYSE: NVO) announced today that the European Commission (EC) has granted marketing authorization&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70085,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[4361,148,860,86,15],"class_list":["post-70084","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hot-targets","tag-novo-nordisk","tag-nyse-nvo","tag-obesity","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE: NVO) announced today that the European Commission (EC) has granted marketing authorization for Wegovy pill (once-daily oral semaglutide 25 mg) for treating adults with obesity (BMI \u226530 kg\/m\u00b2) or overweight (BMI \u226527 kg\/m\u00b2) with at least one weight-related comorbidity. The approval follows a positive opinion from the European Medicines Agency&#039;s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued in May 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70084\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk (NYSE: NVO) announced today that the European Commission (EC) has granted marketing authorization for Wegovy pill (once-daily oral semaglutide 25 mg) for treating adults with obesity (BMI \u226530 kg\/m\u00b2) or overweight (BMI \u226527 kg\/m\u00b2) with at least one weight-related comorbidity. The approval follows a positive opinion from the European Medicines Agency&#039;s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued in May 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70084\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T08:13:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T08:13:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70084#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70084\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment\",\"datePublished\":\"2026-07-16T08:13:25+00:00\",\"dateModified\":\"2026-07-16T08:13:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70084\"},\"wordCount\":448,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70084#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1602.webp\",\"keywords\":[\"Hot targets\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70084#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70084\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70084\",\"name\":\"Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70084#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70084#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1602.webp\",\"datePublished\":\"2026-07-16T08:13:25+00:00\",\"dateModified\":\"2026-07-16T08:13:26+00:00\",\"description\":\"Novo Nordisk (NYSE: NVO) announced today that the European Commission (EC) has granted marketing authorization for Wegovy pill (once-daily oral semaglutide 25 mg) for treating adults with obesity (BMI \u226530 kg\\\/m\u00b2) or overweight (BMI \u226527 kg\\\/m\u00b2) with at least one weight-related comorbidity. The approval follows a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued in May 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70084#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70084\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70084#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1602.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70084#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk (NYSE: NVO) announced today that the European Commission (EC) has granted marketing authorization for Wegovy pill (once-daily oral semaglutide 25 mg) for treating adults with obesity (BMI \u226530 kg\/m\u00b2) or overweight (BMI \u226527 kg\/m\u00b2) with at least one weight-related comorbidity. The approval follows a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued in May 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70084","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment","og_description":"Novo Nordisk (NYSE: NVO) announced today that the European Commission (EC) has granted marketing authorization for Wegovy pill (once-daily oral semaglutide 25 mg) for treating adults with obesity (BMI \u226530 kg\/m\u00b2) or overweight (BMI \u226527 kg\/m\u00b2) with at least one weight-related comorbidity. The approval follows a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued in May 2026.","og_url":"https:\/\/flcube.com\/?p=70084","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-16T08:13:25+00:00","article_modified_time":"2026-07-16T08:13:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70084#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70084"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment","datePublished":"2026-07-16T08:13:25+00:00","dateModified":"2026-07-16T08:13:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70084"},"wordCount":448,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70084#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1602.webp","keywords":["Hot targets","Novo Nordisk","NYSE: NVO","Obesity","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70084#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70084","url":"https:\/\/flcube.com\/?p=70084","name":"Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70084#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70084#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1602.webp","datePublished":"2026-07-16T08:13:25+00:00","dateModified":"2026-07-16T08:13:26+00:00","description":"Novo Nordisk (NYSE: NVO) announced today that the European Commission (EC) has granted marketing authorization for Wegovy pill (once-daily oral semaglutide 25 mg) for treating adults with obesity (BMI \u226530 kg\/m\u00b2) or overweight (BMI \u226527 kg\/m\u00b2) with at least one weight-related comorbidity. The approval follows a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued in May 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70084#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70084"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70084#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1602.webp","width":1080,"height":608,"caption":"Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70084#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70084"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70084\/revisions"}],"predecessor-version":[{"id":70086,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70084\/revisions\/70086"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70085"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70084"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70084"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}